Eli Lilly Partners with Cipla for Tirzepatide Distribution and Promotion in India

Eli Lilly Partners with Cipla for Tirzepatide Distribution and Promotion in India

On October 24, 2025, Eli Lilly and Company announced a strategic collaboration with Cipla Limited, a leading Indian pharmaceutical firm, to distribute and promote Yurpeak® (tirzepatide injection) in India. Tirzepatide, a dual GLP-1 and GIP receptor agonist, is approved for chronic weight management in adults with obesity or overweight accompanied by at least one weight-related comorbidity. Marketed as Yurpeak® in this partnership, it represents Lilly’s entry into India’s burgeoning market for anti-obesity therapies.

FDA Approves Oral Semaglutide for CV Risk Reduction in High-Risk Type 2 Diabetes

FDA Approves Oral Semaglutide for CV Risk Reduction in High-Risk Type 2 Diabetes

On October 23, 2025, the U.S. Food and Drug Administration (FDA) expanded the label for Novo Nordisk’s oral semaglutide (Rybelsus®) to include reduction of major adverse cardiovascular events (MACE)—cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke—in adults with type 2 diabetes mellitus (T2D) and either established cardiovascular disease or high cardiovascular risk, irrespective of prior CV event history. This approval establishes oral semaglutide as the first oral GLP-1 receptor agonist with a cardiovascular indication for both primary and secondary prevention.

Orforglipron Outperforms Dapagliflozin and Placebo in Phase 3 T2D Trials

Orforglipron Outperforms Dapagliflozin and Placebo in Phase 3 T2D Trials

Eli Lilly and Company announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials evaluating orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for type 2 diabetes management. In ACHIEVE-2, orforglipron (3 mg, 12 mg, 36 mg) was compared to dapagliflozin (10 mg) in adults with type 2 diabetes inadequately controlled on metformin. The trial met its primary endpoint, with orforglipron achieving A1C reductions of up to 1.7% (efficacy estimand) compared to 0.8% for dapagliflozin at 40 weeks.

Sitagliptin Preserves Bone Density in Diabetic Women: SLowDOWN Trial

Sitagliptin Preserves Bone Density in Diabetic Women: SLowDOWN Trial

Women with type 2 diabetes face elevated risks of osteoporosis and fractures, potentially exacerbated by hyperglycemia and medications. Dipeptidyl peptidase-4 inhibitors (DPP4-Is) like sitagliptin may protect bone health by modulating bone metabolism and inflammation, but clinical evidence is sparse. The SLowDOWN trial evaluated the efficacy and safety of sitagliptin on bone mineral density (BMD) and related biomarkers in women with type 2 diabetes over 52 weeks.

Early Dapagliflozin-Sitagliptin FDC Enhances Glycemic and Cardiometabolic Outcomes in T2DM

Early Dapagliflozin-Sitagliptin FDC Enhances Glycemic and Cardiometabolic Outcomes in T2DM

The REALIZE Study, a retrospective observational analysis, assessed the effectiveness and safety of early initiation of a fixed-dose combination (FDC) of dapagliflozin (SGLT-2 inhibitor) and sitagliptin (DPP-4 inhibitor) in 250 Indian patients with type 2 diabetes mellitus (T2DM) across five centers. Eligible patients, aged 18-59 years with a BMI ≥25 kg/m² and HbA1c between 7.0% and 10.5%, were prescribed the FDC for 112 ± 20 days.

Clopidogrel vs. Aspirin for Primary Prevention in High-Risk Type 2 Diabetes

Clopidogrel vs. Aspirin for Primary Prevention in High-Risk Type 2 Diabetes

Atherosclerotic cardiovascular disease (ASCVD) poses a major threat to patients with type 2 diabetes, even without prior events. While aspirin is recommended for primary prevention in high-risk diabetic individuals, its benefits are offset by increased bleeding risks, particularly gastrointestinal (GI) bleeding. Clopidogrel, a P2Y12 inhibitor, has shown fewer GI events in secondary prevention trials, but its role in primary prevention remains unclear. This study aimed to compare the effectiveness and safety of clopidogrel versus aspirin in high- and very high-risk diabetic patients without ASCVD, using real-world data from the Korean National Health Insurance Service–National Sample Cohort (NHIS-NSC) from 2010-2019.